<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322761</url>
  </required_header>
  <id_info>
    <org_study_id>Morten_Riemenschneider_PhD</org_study_id>
    <nct_id>NCT03322761</nct_id>
  </id_info>
  <brief_title>Early Exercise Efforts in Multiple Sclerosis</brief_title>
  <official_title>Exercise as a Supplemental Treatment Strategy Early in the Disease Course of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to investigate whether early exercise efforts can expand the use of exercise&#xD;
      in Multiple sclerosis (MS), from symptom treatment only, to early supplementary&#xD;
      disease-modifying treatment.&#xD;
&#xD;
      The study will be conducted in a randomized and controlled manner, with single blinding.&#xD;
      Participants will be allocated to either a systematic aerobic exercise intervention or an&#xD;
      educational programme on exercise and physical activity. Both interventions will last 1 year,&#xD;
      and involve a 1 year follow-up period.&#xD;
&#xD;
      It is hypothesized that early exercise efforts can modify the disease activity and disability&#xD;
      progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) is an autoimmune and neurodegenerative disease in the central nervous&#xD;
      system (CNS), characterized by a complex pathogenesis and heterogeneous symptoms. The&#xD;
      histopathological hallmark of the disease is sclerotic lesions. These inflammatory lesions&#xD;
      manifests as disabling relapses, and the number of relapses in the first few years after&#xD;
      disease onset is associated with progression of disability, with a higher number of relapses&#xD;
      leading to a more rapid progression. In addition, diffuse neurodegeneration seems to occur&#xD;
      early in the disease, and even though it is not always clinically evident it is associated&#xD;
      with disease progression. A reduction in relapse rate and neurodegeneration early in the MS&#xD;
      disease course may slow the progression of disabilities and can possibly reduce overall&#xD;
      disease burden. For the individual person with MS (pwMS) a reduction in overall disease&#xD;
      burden will often improve quality of life, and since MS is a lifelong disease this is of&#xD;
      great interest. Preventing disability in pwMS is also highly relevant in a societal&#xD;
      perspective, as it lowers the large costs associated with increased disability. As a&#xD;
      consequence, the importance of early treatment have been emphasized.&#xD;
&#xD;
      Treatment of MS have seen great advances in the recent years, resulting in an increasing&#xD;
      number of available disease-modifying treatments (DMT). Despite the fact that the current&#xD;
      DMTs favourable alter a number of clinical outcomes and the course of the disease, it is&#xD;
      still a serious and deteriorating condition with significant disease activity, impaired&#xD;
      neurological functions and thus progression of disabilities. New and supplemental treatment&#xD;
      strategies are therefore still warranted, and exercise have gained attention as a safe and&#xD;
      tolerable rehabilitation strategy. Recently, exercise furthermore have gained substantial&#xD;
      attention, as the first indications of neuroprotective and disease-modifying effects of&#xD;
      exercise has been published. However, despite the focus on early treatment in medical DMTs no&#xD;
      studies have investigated the effects of exercise as a supplemental treatment strategy early&#xD;
      in the disease course of MS.&#xD;
&#xD;
      Consequently, the purpose of this study is to investigate the effects of early exercise&#xD;
      efforts on disease activity and disability progression. In a sub-group the effects will&#xD;
      furthermore be investigated on brain volume, specific brain regions, and inflammation.&#xD;
&#xD;
      It is hypothesized that early exercise efforts can modify the disease activity and disability&#xD;
      progression, by reducing the relapse rate, the progression of Multiple Sclerosis Functional&#xD;
      Composite (MSFC) and Expanded Disability Status Scale (EDSS) scores. The rate of brain&#xD;
      atrophy and the lesion load, obtained by MRI scans, is also hypothesized to be reduced. This&#xD;
      is expected to be due to an exercise-induced reduction in inflammation.&#xD;
&#xD;
      The study will be a randomised and controlled study with randomisation to either an&#xD;
      systematic aerobic exercise intervention or an educational programme on exercise and physical&#xD;
      activity. Both interventions are in addition to standard treatment, and will last 1 year. The&#xD;
      exercise intervention will consist of 2 supervised exercise sessions per week in the complete&#xD;
      duration of the study, while the standard treatment plus exercise education program will&#xD;
      consist of 4 educational sessions on the health benefits associated with exercise and&#xD;
      physical activity held every third month throughout the intervention period. The training in&#xD;
      the exercise group will be aerobic exercise (running, cycling, rowing or on a cross-trainer)&#xD;
      planned by exercise physiologists and performed in a progressive manner. To allow handling of&#xD;
      a large number of participants, who is also geographically spread, the exercise intervention&#xD;
      will be locally anchored, but at the same time supervised by student employees from Section&#xD;
      for Sports Science and controlled by internet- and telephonic communication. In addition to&#xD;
      the two intervention groups, data from The Danish MS registry will serve as population based&#xD;
      standard treatment control data. All groups will be followed up 1 year after cessation of the&#xD;
      interventions.&#xD;
&#xD;
      To set the estimated number of participants a two-sample two-sided power calculation has been&#xD;
      conducted. The basis for this calculation is an report from Tallner et al. who have shown a&#xD;
      difference in relapse rate during a two-year period (equal to our 1 year intervention, and 1&#xD;
      year follow-up) of 0.65 relapses between physically active and physically inactive MS&#xD;
      patients (active: 0.95 +/- 0.97 relapses in 2 years ; inactive: 1.60 +/- 1.64 relapses in 2&#xD;
      years). 83 patients with MS should be enrolled in each intervention group (a 20% drop-out&#xD;
      rate has been included). Newly published data on the brain atrophy in percentage of total&#xD;
      brain volume after 24 weeks of resistance training have been the basis for a similar&#xD;
      calculation of the number of participants in the sub-group, from whom MRI-scans and blood&#xD;
      samples will be obtained. 41 participants from each intervention group should form this&#xD;
      sub-group.&#xD;
&#xD;
      MS is a complex disease with heterogenous symptoms, and by combining the disciplines of&#xD;
      exercise physiology, neurology and radiology this study can be the first long-term and&#xD;
      large-scale exercise study to investigate the possible neuroprotective and disease-modifying&#xD;
      effects of exercise when initiated early in the disease course of MS. Consequently, this&#xD;
      project has the potential to change present clinical practice and generate further attention&#xD;
      to exercise, not only as symptom treatment, but also as an supplemental disease-modifying&#xD;
      treatment strategy early in the course of MS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Annual Relapse Rate (ARR)</measure>
    <time_frame>ARR, 1 year intervention; 1 year follow up.</time_frame>
    <description>Number of relapses, registered and validated by neurologist, on annual basis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage brain volume change</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Brain atrophy will be measured from MRI-scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite (MSFC)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Composite score from Timed 25-Feet Walk Test (T25FWT), 9-Hole Peg Test (9HPT), Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) score</measure>
    <time_frame>Baseline, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Disability status score assessed and registered by neurologist. The scale ranges from 0-10 in 0.5 unit increments representing higher levels of disability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional capacity, Six-minute walk test (6MWT)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Distance covered during a six-minute maximal walking test</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional capacity, Six-spot-step-test (SSST)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>SSSt is a measure of walking ability, balance and coordination. Measured as the time to complete the six-spot course.</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional capacity, Accelerometry</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Measurement of level of physical activity by wearing a accelerometer for 7 days at each timepoint. Measured in counts/min.</description>
  </other_outcome>
  <other_outcome>
    <measure>Aerobic capacity</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Maximal oxygen uptake test on bike ergometer, measured by indirect calorimetry.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognition, Symbol Digit Modality Test (SDMT)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Assessment of cognitive function (processing speed), with a higher number of correct answers in the test representing better cognitive function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognition, Paced Auditory Serial Addition Test (PASAT)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Assessment of cognitive function (processing speed and memory), with a higher number of correct answers in the test representing better cognitive function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognition, Selective Reminding Test (SRT)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Assessment of cognitive function (memory), with a higher number of correct answers in the test representing better cognitive function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Short Form Health Survey 36 (SF-36)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Questionnaire assessing health status. The SF-36 consists of eight subscales, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.</description>
  </other_outcome>
  <other_outcome>
    <measure>Multiple Sclerosis Impact Scale 29 (MSIS-29)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Questionnaire assessing the impact of the disease. 20 questions measure the physical impact, and 9 questions measure the psychological impact. Each question is scored from 1-5. A greater score is equal to a larger impact.</description>
  </other_outcome>
  <other_outcome>
    <measure>Multiple Sclerosis Walking Scale 12 (MSWS-12)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Questionnaire assessing the impact of the disease on walking. Each question is scored from 1-5 and then summed and transformed to a 0-100 scale. Higher scores indicate a greater impact on walking.</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Questionnaire assessing the effects of fatigue on physical, cognitive and psychosocial functioning. The score of the MFIS is the sum of the scores for the 21 items. A higher score represents a higher impact of fatigue, in general or in relation to one of the above mentioned areas.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of lesions</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Number of lesions, measured by MRI-scanning.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lesion load</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Volume of lesions, measured by MRI-scanning.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kurtosis</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>MRI-measure of microstructural changes in the brain</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Blood samples will be analyzed for key inflammatory cytokines</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Systematic exercise training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weekly supervised aerobic exercise trainings for 48 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Educational program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Educational program on physical activity and health, consisting of four educational sessions in the intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Data from The Danish MS Registry will serve as control-data for standard treatment alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Systematic exercise training</intervention_name>
    <description>Combination of standard medical treatment and systematic early exercise training in persons with MS.</description>
    <arm_group_label>Systematic exercise training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Educational program</intervention_name>
    <description>Informations regarding health benefits of physical activity and exercise.</description>
    <arm_group_label>Educational program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
          -  Definite diagnosis with Relapsing remitting multiple sclerosis (RRMS)&#xD;
&#xD;
          -  No more than 2 years since diagnosis&#xD;
&#xD;
          -  Expectedly able to carry out high intensity aerobic training&#xD;
&#xD;
          -  Able to transport themselves to and from training sessions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Dementia, alcohol abuse, or pacemaker&#xD;
&#xD;
          -  Metallic implants, hindering MRI-scans&#xD;
&#xD;
          -  Comorbidities hindering participation in high intensity aerobic training&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Riemenschneider, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for Sport Science, Department of Public Health, Aarhus University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Section for Sport Science, Department of Public Health, University of Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7.</citation>
    <PMID>18970977</PMID>
  </reference>
  <reference>
    <citation>Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: An evidence-based view. Mult Scler Relat Disord. 2015 Sep;4(5):460-469. doi: 10.1016/j.msard.2015.07.007. Epub 2015 Jul 17. Review.</citation>
    <PMID>26346796</PMID>
  </reference>
  <reference>
    <citation>Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005 Apr;11(2):232-9. Review.</citation>
    <PMID>15794399</PMID>
  </reference>
  <reference>
    <citation>Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.</citation>
    <PMID>24485135</PMID>
  </reference>
  <reference>
    <citation>Elovaara I. Early treatment in multiple sclerosis. J Neurol Sci. 2011 Dec;311 Suppl 1:S24-8.</citation>
    <PMID>22206762</PMID>
  </reference>
  <reference>
    <citation>Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler. 2008 Jan;14(1):35-53. Epub 2007 Sep 19. Review.</citation>
    <PMID>17881393</PMID>
  </reference>
  <reference>
    <citation>Kj√∏lhede T, Siemonsen S, Wenzel D, Stellmann JP, Ringgaard S, Pedersen BG, Stenager E, Petersen T, Vissing K, Heesen C, Dalgas U. Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis? Mult Scler. 2018 Sep;24(10):1356-1365. doi: 10.1177/1352458517722645. Epub 2017 Jul 28.</citation>
    <PMID>28752800</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Exercise</keyword>
  <keyword>Disease-modifying treatment</keyword>
  <keyword>Early treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be stored in The Danish National Archives after completion of the project, and data can be accessed through request to The Danish National Archives.</ipd_description>
    <ipd_time_frame>The data will become available after completion of the project, expectedly January 2021. The Danish National Archives stores data without a time frame (forever).</ipd_time_frame>
    <ipd_access_criteria>Sharing of data can happen upon request to The Danish National Archives.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

